Continued Tafasitamab Treatment for Blood Cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial allows people with blood cancers who are already benefiting from tafasitamab treatment in another study to keep receiving it. It helps ensure you can continue this therapy without interruption.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently in a tafasitamab study and still getting the drug.
- Your body is handling tafasitamab well, with no severe side effects.
- Your cancer has not worsened (it is stable, partially or fully responding).
- You and your doctor agree that you are getting benefit from tafasitamab.
- You are able to follow the study rules and visit schedule.
- You agree to use contraception if needed, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests tafasitamab in children and teens with B-lineage acute lymphoblastic leukemia (ALL) that has come back or did not respond. It is mainly for patients with specific high-risk leukemia changes and/or leukemia markers that stay after stem cell transplant or CAR T-cell therapy.
This study lets people who are already benefiting from the cancer drug tucatinib keep taking it after their original study ends. It aims to provide continued access to the treatment while monitoring safety and effectiveness.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
This trial studies tafasitamab plus rituximab to treat a type of lymphoma called post-transplant lymphoproliferative disorder (PTLD) in adults after a solid organ transplant. It’s aimed at helping stop the PTLD when it can be measured and before you’ve had PTLD treatment beyond limited measures like steroid or reducing anti-rejection drugs.
This early-phase study tests whether tazemetostat and palbociclib can help people with acute myeloid leukemia (AML) that has come back or did not respond to treatment. It looks for safety and early signs of how well the treatment works.
This study looks at how well a combination of two drugs, tafasitamab and lenalidomide, works for people with a type of lymphoma (DLBCL) that has come back or hasn't responded to treatment. After the combination, patients continue with tafasitamab alone. This is for patients who cannot have a stem cell transplant.
Hear when a new Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.